The sirolimus | 合法醫療器材資訊網

由AAbizaid著作·2012·被引用15次—Thesirolimus-elutingCypherSelectcoronarystentforthetreatmentofbare-metalanddrug-elutingstentrestenosis:insightsfromthee-SELECT(Multicenter ...

Objectives: This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselected, real-world patients.

Background: There is paucity of consistent data on DES for the treatment of ISR, especially, DES ISR.

Methods: The e-SELECT (Multicenter Post-Market Surveillance) registry is a Web-based, multicenter and international registry encompassing virtually all subsets of patients and lesions treated with at least 1 SES during the period from 2006 to 2008. We enrolled in this pre-specified subanalysis all patients with at least 1 clinically relevant BMS or DES ISR treated with SES. Primary endpoint was major adverse cardiac events and stent thrombosis rate at 1 year.